Key result
Polygenic risk scores for Brugada syndrome, baseline QRS, baseline Type II/III ECG, and family history independently predicted ajmaline-induced Type I Brugada syndrome ECG (C-statistic 0.74).
Why the study?
Sodium-channel blockers are associated with arrhythmia, but the variability of cardiac electrical response remains unexplained.
Can polygenic risk scores predict ajmaline-induced ECG changes and the development of Type I Brugada syndrome ECG in patients with suspected Brugada syndrome?
Population
1368 patients that underwent ajmaline infusion for suspected BrS
Comparison
Polygenic risk scores for PR interval, QRS duration, and BrS
Design
Observational cohort study with derivation and bootstrap validation
Authors
Loading...
PRS may refine ajmaline response prediction; leaves open clinical adoption pending independent validation.
Observational (n=1,368)
Can polygenic risk scores predict ajmaline-induced ECG changes and the development of Type I Brugada syndrome ECG in patients with suspected Brugada syndrome?
Effect estimate: C-statistic 0.74
Polygenic risk scores combined with baseline clinical and ECG characteristics can accurately predict the development of a diagnostic drug-induced Type I Brugada syndrome ECG.
Tadros et al. (2019) conducted an observational in Suspected Brugada syndrome (n=1,368). Polygenic risk scores (PRS) and clinical factors was evaluated on Occurrence of a Type I Brugada syndrome ECG (C-statistic 0.74). Polygenic risk scores for Brugada syndrome, baseline QRS, baseline Type II/III ECG, and family history independently predicted ajmaline-induced Type I Brugada syndrome ECG (C-statistic 0.74).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: